All In Biotech

Drug Trial Radar · NCT06353386

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

MK-5684-01A Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 220 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

220

Planned (sponsor's estimate)

Start

May 20, 2024

Primary completion

Jan 15, 2029

Study completion Jan 15, 2029

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Orion Corporation, Orion Pharma
First posted
Apr 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Substudy 01A is part of a larger research study that is testing experimental treatments for metastatic castration-resistant prostate cancer (mCRPC). The larger study is the umbrella study (U01). The goal of substudy 01A is to evaluate the safety and efficacy of opevesostat-based treatment combinations, or as a single agent, in participants with mCRPC. This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for the opevesostat-based treatment combinations. There will be no hypothesis testing in this study.

Conditions

  • Prostatic Neoplasms, Castration-Resistant

Interventions

  • OpevesostatDrug

    Oral Tablet

  • OlaparibDrug

    Oral Tablet

  • DocetaxelDrug

    IV Infusion

  • CabazitaxelDrug

    IV Infusion

  • Fludrocortisone acetateDrug

    Oral Tablet

  • DexamethasoneDrug

    Oral Tablet

  • PrednisoneDrug

    Oral Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants who experience one or more dose-limiting toxicities (DLTs)Time frame: Up to approximately 28 days
  2. Number of participants who experience one or more adverse events (AEs)Time frame: Up to approximately 46 months
  3. Number of participants who discontinue study intervention due to an AETime frame: Up to approximately 46 months
  4. Prostate-specific antigen (PSA) response rateTime frame: Up to approximately 46 months

Locations

77 sites in 20 countries. Site status is shown where the registry gives one.

  • UCSD Moores Cancer Center ( Site 0039)

    La Jolla, California

  • UCLA Hematology/Oncology - Santa Monica ( Site 0044)

    Los Angeles, California

  • University of Miami Hospital and Clinics, Sylvester Cancer Center-Cancer Research Services ( Site 0051)

    Miami, Florida

  • University of Maryland-Greenebaum Comprehensive Cancer Center ( Site 0049)

    Baltimore, Maryland

  • Rutgers Cancer Institute of New Jersey ( Site 0033)

    New Brunswick, New Jersey

  • University Hospitals Cleveland Medical Center ( Site 0043)

    Cleveland, Ohio

  • MEDICAL COLLEGE OF WISCONSIN-Cancer Center Clinical Trials Office ( Site 0020)

    Milwaukee, Wisconsin

  • Macquarie University-MQ Health Clinical Trials Unit ( Site 0108)

    Macquarie University, New South Wales, Australia

  • Gallipoli Medical Research Ltd-GMRF CTU ( Site 0107)

    Greenslopes, Queensland, Australia

  • Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 0110)

    Melbourne, Victoria, Australia

  • Centre Hospitalier de l'Université de Montréal ( Site 0200)

    Montreal, Quebec, Canada

  • Jewish General Hospital ( Site 0206)

    Montreal, Quebec, Canada

  • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0207)

    Québec, Quebec, Canada

  • CIDO SpA-Oncology ( Site 0302)

    Temuco, Biobio, Chile

  • Clinica Universidad Catolica del Maule-Oncology ( Site 0304)

    Talca, Maule Region, Chile

  • Fundación Arturo López Pérez ( Site 0301)

    Santiago, Region M. de Santiago, Chile

  • Pontificia Universidad Catolica de Chile ( Site 0303)

    Santiago, Region M. de Santiago, Chile

  • Bradfordhill ( Site 0300)

    Santiago, Region M. de Santiago, Chile

  • FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0406)

    Bogotá, Bogota D.C., Colombia

  • Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia ( Site 0402)

    Bogotá, Bogota D.C., Colombia

  • Sociedad De Oncología y Hematología Del Cesar SAS-Oncology ( Site 0400)

    Valledupar, Cesar Department, Colombia

  • IMAT S.A.S ( Site 0404)

    Montería, Departamento de Córdoba, Colombia

  • Fundación Valle del Lili-Oncology CIC ( Site 0403)

    Cali, Valle del Cauca Department, Colombia

  • Herlev and Gentofte Hospital ( Site 0501)

    Copenhagen, Capital Region, Denmark

  • Aalborg Universitetshospital, Syd ( Site 0503)

    Aalborg, North Denmark, Denmark

  • Vaasan Keskussairaala ( Site 0603)

    Vaasa, Pohjanmaa, Finland

  • Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus) ( Site 0604)

    Helsinki, Uusimaa, Finland

  • Docrates Syöpäsairaala ( Site 0602)

    Helsinki, Uusimaa, Finland

  • Hôpital Européen Georges Pompidou-Service d'Oncologie Médicale ( Site 0702)

    Paris, France

  • Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest ( Site 0703)

    Bordeaux, Aquitaine, France

  • Hopitaux Universitaires de Strasbourg ( Site 0700)

    Strasbourg, Bas-Rhin, France

  • Gustave Roussy ( Site 0701)

    Villejuif, Île-de-France Region, France

  • Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 0800)

    Berlin, Germany

  • Universitaetsklinikum Hamburg-Eppendorf-Onkologisches Zentrum ( Site 0804)

    Hamburg, Germany

  • Universitaetsklinikum Heidelberg ( Site 0805)

    Heidelberg, Baden-Wurttemberg, Germany

  • Universitaetsklinikum Tuebingen-Urologie ( Site 0801)

    Tübingen, Baden-Wurttemberg, Germany

  • klinikum rechts der isar der technischen universität münchen-Urologische Klinik und Poliklinik ( Site 0802)

    Munich, Bavaria, Germany

  • Cork University Hospital ( Site 0902)

    Cork, Ireland

  • Tallaght University Hospital ( Site 0900)

    Dublin, Ireland

  • St. Vincent's University Hospital ( Site 0901)

    Dublin, Dublin, Ireland

Showing 40 of 77 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.